Fabre-Kramer Pharmaceuticals, Inc. Fabre-Kramer Pharmaceuticals, Inc.
  • About Fabre-Kramer
  • Pipeline
  • Leadership
  • Advisors and Consultants
  • Partnering
  • News
Contact

Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUA™, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults

September 28, 2023 admin Press Releases No comments yet

Fabre-Kramer Partners with Mission Pharmacal for Future Commercial Manufacture of Novel Mechanism Antidepressant Travivo™ (Gepirone ER) Tablets

Read more

Fabre-Kramer Pharmaceuticals Announces FDA Acceptance of NDA Resubmission as Complete Response and Assignment of PDUFA Regulatory Action Date

January 27, 2023 admin Press Releases No comments yet

Fabre-Kramer Partners with Mission Pharmacal for Future Commercial Manufacture of Novel Mechanism Antidepressant Travivo™ (Gepirone ER) Tablets

Read more

Fabre-Kramer Submits NDA Amendment for EXXUA™ for Treatment of Major Depressive Disorder

January 5, 2023 admin Press Releases No comments yet

Fabre-Kramer Partners with Mission Pharmacal for Future Commercial Manufacture of Novel Mechanism Antidepressant Travivo™ (Gepirone ER) Tablets

Read more

Mission Pharmacal to Manufacture Fabre-Kramer’s Novel Antidepressant Travivo™ (Gepirone HCl) Extended Released Tablets

December 16, 2022 Jennifer Spring Press Releases No comments yet

Fabre-Kramer Partners with Mission Pharmacal for Future Commercial Manufacture of Novel Mechanism Antidepressant Travivo™ (Gepirone ER) Tablets

Read more

Antidepressants Worsen Sexual Dysfunction and Depression?

December 16, 2022 Jennifer Spring Press Releases No comments yet

Currently available antidepressants may aggravate sexual dysfunction and make depression worse, a new survey of US adults with major depressive disorder (MDD) suggests.

Read more

Patient Experience Demonstrates Pressing Need for New Treatment Options

December 16, 2022 Jennifer Spring Press Releases No comments yet

Mental Health Survey Reveals Available Antidepressants Aggravate Sexual Dysfunction and Make Depression Worse

Read more

Travivo™ Demonstrates Substantial Evidence of Effectiveness in Treatment of Major Depressive Disorders

December 16, 2022 Jennifer Spring Press Releases No comments yet

FDA Rules Favorably On Efficacy Of Travivo™ (Gepirone ER) For Treatment Of Major Depressive Disorder

Read more

Office of New Drugs Director John Jenkins M.D. will review Gepirone data and analysis

December 16, 2022 Jennifer Spring Press Releases No comments yet

Fabre-Kramer Looks Forward to FDA’s Decision on Gepirone ER for the Treatment of Major Depressive Disorder

Read more
Press Releases
  • Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUA™, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults September 28, 2023
  • Fabre-Kramer Pharmaceuticals Announces FDA Acceptance of NDA Resubmission as Complete Response and Assignment of PDUFA Regulatory Action Date January 27, 2023
  • Fabre-Kramer Submits NDA Amendment for EXXUA™ for Treatment of Major Depressive Disorder January 5, 2023
  • Mission Pharmacal to Manufacture Fabre-Kramer’s Novel Antidepressant Travivo™ (Gepirone HCl) Extended Released Tablets January 3, 2018
  • Antidepressants Worsen Sexual Dysfunction and Depression? October 20, 2016
Social
Fabre-Kramer

Fabre-Kramer Pharmaceuticals, Inc is a leader in identifying, developing, and commercializing psychotropic drugs for the treatment of psychiatric and neurologic disorders.

Pipeline
  • EXXUA™
  • FKB01MD
  • FKW00GA
  • FKF02SC
  • FKK01PD
Contact

info@fabrekramer.com

Fabre-Kramer Pharmaceuticals, Inc. All Rights Reserved

Let's get in touch

Give us a call or drop by anytime, we endeavour to answer all enquiries within 24 hours on business days.